Transcriptome

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Disease, Transcriptome, Malignancy, Neoplasm, DNA, Genome, Workflow, AACR, Doctor of Philosophy, Phenotype, Genomics, SNV, Ageing, CNV, Mobile phone

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
  • “Tumor heterogeneity is a key challenge for researchers in the cancer research field.
  • As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
  • “Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.

BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics

Retrieved on: 
Wednesday, March 13, 2024
Health Technology, Other Health, Technology, Oncology, General Health, Medical Devices, Neurology, Other Technology, Cardiology, Science, Biotechnology, Software, Other Science, Health, Research, PTA, Genome, Gene expression, Transcriptome, DNA, RNA, Figure skating jumps, Marketing, Workflow, Data, Genomics, SVS, WGA, Antibiotics

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.
  • As part of these new kit configurations, total workflow time has been reduced to under eight hours for both products.
  • “These new core kits provide researchers with an optimized and validated workflow that delivers industry-leading single-cell multiomic performance,” said Suresh Pisharody, CEO, BioSkryb.
  • The ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit leverages its PTA-based WGA technology to couple each single cell’s whole genome with its full-length whole transcriptome.

10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay

Retrieved on: 
Tuesday, March 26, 2024
Transcriptome, Histology, 10x Genomics, History, Space Ranger, Integration, Genomics, H&E, Gene expression, Microscope

PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution.

Key Points: 
  • Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution
    PLEASANTON, Calif., March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product.
  • "Visium HD is a game-changer for spatial discovery research, and our team couldn't be more proud and excited to get this long-awaited product into the hands of our customers," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics.
  • Combining the power of whole transcriptome spatial discovery with histological insights, Visium HD enables comprehensive characterization of FFPE tissue samples.
  • Best-in-class sequencing-based spatial transcriptomics data: Map gene expression with precision and high confidence using a simple and robust workflow exclusively available on Visium CytAssist.

10x Genomics Begins Commercial Shipments of Chromium GEM-X Products

Retrieved on: 
Wednesday, March 13, 2024
Associate, Transcriptome, Biology, University, Chromium, Architecture, Gene, Research, Genomics, Cell, Mobile phone

PLEASANTON, Calif., March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.

Key Points: 
  • "It's been incredible to see the enthusiasm from customers since we first announced the GEM-X architecture last month, and we can't wait to get these new products in researchers' hands," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics.
  • "GEM-X sets a new standard for single cell analysis and gives customers important performance advantages that will immediately benefit their research.
  • This is one of multiple steps we have planned to make single cell more accessible for all."
  • "GEM-X, with its exceptional transcript capture, can enhance our capacity to differentiate cell types, spot rare cells and decode regulatory pathways.

Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024

Retrieved on: 
Monday, March 4, 2024
Phenotype, Breakfast, Informatics, EST, Booth, Exome, Common, Nursing care plan, Down syndrome, Genetics, American College, ACMG, Genetic testing, M.D, Automation, Medical genetics, Transcriptome, Research, Whole genome sequencing, Pharmaceutical industry

HOUSTON, March 04, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will showcase its latest advancements and research discoveries at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting on March 12-16 in Toronto, Canada.

Key Points: 
  • The presentations shed light on cutting-edge developments in genetic analysis, diagnostic interpretation, and clinical results, underscoring Baylor Genetics’ mission to translate scientific innovation into accessible clinical solutions that improve patient outcomes and advance precision diagnostics.
  • "These presentations reflect our ongoing commitment to advancing the field of genetics and empowering patients, providers, and partners with insights and innovations to transform healthcare and improve lives."
  • Customers and partners interested in attending the breakfast can request an invitation and register here or inquire onsite at the Baylor Genetics booth.
  • Learn more about ACMG’s Annual Clinical Genetics Meeting through the conference website and visit the Baylor Genetics’ website to explore the company’s genetic testing capabilities.

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Retrieved on: 
Friday, March 8, 2024
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Gene expression profiling, Breast cancer, Neoplasm, Taxane, Woman, Transcriptome, MD, MBCC, Cyclophosphamide, Anthracycline, PCR, MammaPrint, Risk, Conference, Symantec Endpoint Protection, AC-T, Patient, MP, Diagnosis, Triple-negative breast cancer, Blueprint, TC, Medical imaging

The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.

Key Points: 
  • The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.
  • ), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR).
  • The second poster, titled Prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.
  • Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population.

Comprehensive Study from 50 Top Scientists Details Five Cutting-edge Advances in Biomedical Engineering and Their Applications in Medicine

Retrieved on: 
Thursday, February 22, 2024
Health Technology, Data Management, Technology, Nanotechnology, Stem Cells, Biometrics, Medical Devices, Neurology, Genetics, Artificial Intelligence, Science, Biotechnology, Other Science, Health, Research, Paper, Therapy, Tissue engineering, Transcriptome, Gene editing, AI, Education, Substance abuse, Immunotherapy, Epigenome, Growth, Physiology, Interface, Cell, Vaccine, Behavior, Protein engineering, Biomedicine, University, Biomedical engineering, Guideline, Biological engineering, Patient, Genome, Johns Hopkins University, Genomics, Diagnosis, Tissue, DNA, Immune system, Brain, Medical imaging

Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.

Key Points: 
  • Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.
  • By focusing on these five areas, the consortium has laid out a roadmap for future research and funding.
  • Advanced technologies, such as wearable sensors and digital twins, can provide the basis of a solution to this challenge.
  • Despite the rapid advances in genomics in the past few decades, there are obstacles remaining in our ability to engineer genomic DNA.

Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance

Retrieved on: 
Wednesday, February 21, 2024
Research, Technology, Genetics, Health Technology, Software, Stem Cells, Biotechnology, General Health, Health, Science, WT, Fixation, RNA, Transcriptome, Cell, Workflow, Chemistry, Fine chemical

Parse Biosciences , a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ Whole Transcriptome products.

Key Points: 
  • Parse Biosciences , a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ Whole Transcriptome products.
  • Available to ship in mid-March, Evercode Whole Transcriptome version 3 kits offer researchers a more streamlined workflow, more flexible and higher throughput fixation, and optimized reagents for improved sensitivity in gene detection.
  • With the new version, customers will enjoy a more streamlined and flexible workflow, helping them move from samples to results more quickly.
  • Parse is currently taking orders for Evercode Whole Transcriptome v3.

Parse Biosciences Partners with INTEGRA Biosciences for Automated Single Cell Workflows

Retrieved on: 
Tuesday, February 6, 2024
Software, Research, General Health, Professional Services, Technology, Infectious Diseases, Health Technology, Data Analytics, Science, Biotechnology, Stem Cells, Health, Other Science, Laboratory automation, Workflow, Cell, Transcriptome, Society, Laboratory, SLAS, Organization, Fine chemical

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has entered into an agreement with INTEGRA Biosciences to integrate the Assist Plus with built-in Parse Evercode™ single cell protocols.

Key Points: 
  • Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has entered into an agreement with INTEGRA Biosciences to integrate the Assist Plus with built-in Parse Evercode™ single cell protocols.
  • As part of the agreement, Parse will sell a bundled solution composed of Evercode single cell reagents and an application-enabled INTEGRA Assist Plus instrument directly to customers.
  • As part of the deal, Parse customers will be supported by both the Parse Biosciences and INTEGRA field service and sales teams.
  • The Parse Biosciences team will be presenting a poster on the efficiency gained by integrating the INTEGRA Assist Plus with the Evercode protocols at the Society for Laboratory Automation and Screening (SLAS) conference in Boston February 3-7.